secwatch.observer — SEC 8-K summary
======================================

Issuer:     Terns Pharmaceuticals, Inc. (TERN)
CIK:        0001831363
Form:       8-K
Filed at:   2025-02-24T23:59:59+00:00
Accession:  0000950170-25-025635
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Terns Pharma appoints Andrew Gengos as CFO effective Feb 24, 2025
-----------------------------------------------------------------

- Andrew Gengos named CFO effective Feb 24; salary $510K, bonus target 40%, option for 750K shares vesting over 4 years.
- Most recently CFO/Chief Business Officer at Athira Pharma (May 2023-Oct 2024); previously CEO at ImmunoCellular and Neuraltus.
- CEO Amy Burroughs remains CEO but steps down as principal financial officer; David Strauss remains VP Finance and steps down as principal accounting officer.
- Stock option exercise price equals closing price on start date; 25% vests at one year, then monthly over three years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831363/000095017025025635/0000950170-25-025635-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831363/000095017025025635/tern-20250222.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-025635

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer